hotspot -WSS

hotspot

author：fashion 2025-09-07 17:27:42 - browse：9822

LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech Calliditas Therapeutics in a nearly $1.1 billion cash deal, the companies said Tuesday.

The firm’s offer of $19.68 per share amounts to an 83% premium versus Calliditas’ closing price on a Swedish exchange Monday. The Calliditas board has unanimously recommended that shareholders accept the offer, the company said, adding that it “aims to realize the benefits of being part of a larger platform” by being acquired.

Calliditas has an approved drug on the U.S. market called Tarpeyo, which treats a kidney disease called IgA nephropathy. The condition has in recent years attracted interest from a number of pharma companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Cheap, fast test for Zika and dengue could cost just $1

hotspot

WSS

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

Report captures long Covid’s disabling effects and policy challenges

Lilly's Alzheimer's drug donanemab backed by FDA advisers

The system is set up to fail children with medical complexity

Cheap, fast test for Zika and dengue could cost just $1

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

explore

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Drug repurposing or repositioning? The language matters

Statins may not be needed by millions of people, study suggests

Cancer drug shortages should be causing more outrage

Are infertility treatments 'essential' during the Covid

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Deposition: Sackler embraced plan to conceal OxyContin’s strength

Guidelines to prevent youth baseball injuries need more muscle

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Drug repurposing or repositioning? The language matters

Extensive review finds private equity owners jack up cost of care

knowledge

Stanford president’s abrupt resignation sparks debate

ALS patient reclaims some autonomy thanks to wearable 'robot'

Dementia risk linked to living in disadvantaged areas: Study

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Hormonal contraceptives don’t actually treat endometriosis

entertainment

knowledge

hotspot

leisure time